China’s Shanghai Duoning Biotechnology Co., Ltd has announced a strategic licensing deal with compatriot firm Wuhan Kaide Jinuo Biotechnology Co., Ltd. The collaboration aims to establish a professional research team focused on the development and research of the adenovirus technology platform, with the goal of creating an integrated solution for gene therapy. Financial details of the agreement have not been disclosed.
Joint Efforts in Adenovirus Technology and Gene Therapy
The partnership between Shanghai Duoning Biotechnology and Wuhan Kaide Jinuo signifies a significant step towards advancing gene therapy solutions in China. The joint research and development efforts will leverage the adenovirus technology platform, which is recognized for its potential in delivering genetic material to target cells, offering a promising approach for treating various diseases.
Kaide Jinuo’s Background and Expertise
Wuhan Kaide Jinuo Biotechnology Co., Ltd is a wholly owned subsidiary of KingWise, a company specializing in the transformation of oncology diagnosis and treatment achievements. KingWise is known for its first-in-class in vitro diagnostic kit for the integrated detection of human papillomavirus (HPV), showcasing its expertise in the field of molecular diagnostics and biotechnology.-Fineline Info & Tech
